Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …

Rationale. Severe asthma is characterized by inadequate symptom control and by high rate
of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …

Controlled clinical trials have shown the recombinant humanized monoclonal anti-IgE
antibody omalizumab to improve asthma control and reduce symptom exacerbations in …

Objective. Several clinical studies have demonstrated the effectiveness of omalizumab in
patients with severe allergic asthma but the treatment period has always been relatively …

Severe persistent asthma causes a substantial morbidity and mortality burden and is
frequently inadequately controlled despite intensive guideline-based therapy. Targeting …

Objectives: The aim of this study was to assess the stability of the effectiveness of
omalizumab as add-on treatment in 11 patients with severe persistent allergic asthma …

Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

Efficacy of omalizumab in severe asthma is well documented; however, the optimal duration
of the treatment remains unclear. In an open prospective study, we sought to assess the …